Efficacy News and Research

RSS

EPA approves Clorox DISPATCH disinfectant towels registration to fight against C. difficile

The Clorox Company announced today that the U.S. Environmental Protection Agency approved the registration of DISPATCH Hospital Cleaner Disinfectant Towels with Bleach to kill Clostridium difficile spores in five minutes, the fastest C. difficile contact time available.

31 Mar 2011

Abbott launches MitraClip system to treat MR in Australia

Abbott today announced the launch of the company's catheter-based MitraClip system for the treatment of mitral regurgitation in Australia. The MitraClip device, which has received Therapeutic Goods Administration approval, offers a new treatment option for patients suffering from MR, a debilitating heart valve condition.

31 Mar 2011

MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Montelukast Sodium Oral Soluble Film (OSF) under a 505(b)(2) pathway.

30 Mar 2011

BioSante completes patient enrollment in LibiGel Phase III trial against HSDD

BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the second of two pivotal Phase III LibiGel safety and efficacy trials has been completed. Enrollment in the first LibiGel efficacy trial was completed in February.

30 Mar 2011

Pharmasset commences PSI-7977 Phase 2b study against HCV

Pharmasset, Inc. announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C.

30 Mar 2011

Pathfinder cell-based therapy reverses diabetes in mouse model

Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model.

30 Mar 2011

Vexim granted FDA approval for COHESION bone cement

Vexim specialises in medical instruments and the minimally invasive treatment of vertebral fractures. The company recently announced that it had been awarded FDA certification for its flagship product COHESION™, a bone cement for injection into the vertebra for its fixation following minimally invasive spine repair with the company's SpineJack® device, or following conventional vertebroplasty.

30 Mar 2011

Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV

Presidio Pharmaceuticals, Inc. announced today positive preliminary results from a Phase 1b clinical trial of PPI-461, a novel HCV NS5A inhibitor for the treatment of patients with chronic hepatitis C.

30 Mar 2011

Navy sonar experts develop new medical device for stroke detection

A medical device developed by retired U.S. Navy sonar experts, using submarine technology, is a new paradigm for the detection, diagnosis and monitoring of stroke, says a team of interventional radiologists at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

According to a comprehensive global survey of orthopedic surgeons conducted by iData Research, the leading authority in medical device and pharmaceutical market research, orthopedic surgeons prefer 3-cycle hyaluronic-acid viscosupplementation treatment in the U.S., Europe and Latin Ameica, but are willing to try single-injection products such as Synvisc-One from Genzyme and MONOVISC from Anika Therapeutics.

30 Mar 2011

USPTO issues patent to Somaxon's Silenor food effect

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued U.S. patent no. 7,915,307, entitled "Methods of Improving the Pharmacokinetics of Doxepin."

30 Mar 2011

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept's first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH.

30 Mar 2011

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Metabolic Solutions Development Company, a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.

30 Mar 2011

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

Interventional radiologists have been the leaders in the use of intra-arterial yttrium-90 radioembolization, since its introduction in 2000, to treat liver cancer.

29 Mar 2011

PHT announces availability of NetPRO eClinical solution for public

PHT Corporation announced the availability of NetPRO, a browser-based ePRO and eClinRO system that collects patient data via the Internet. PHT is the global innovator in ePRO and PRO solutions that maximize the collection of high-quality data from clinical trial patients.

29 Mar 2011

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo.

29 Mar 2011

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Interventional radiologists have completed the first human randomized controlled trial of therapeutic renal denervation or RDN—a procedure that uses a catheter-based probe inserted into the renal artery that emits high-frequency energy to deactivate the nerves near the kidneys that are linked to high blood pressure.

29 Mar 2011

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Onyx Pharmaceuticals, Inc. today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.

29 Mar 2011

International Phase II trial to study LY2181308 efficacy in patients with lung cancer

Cancer Research UK scientists in Oxford are trialling an experimental drug to treat lung cancer patients who have stopped responding to initial chemotherapy treatment. The trial will take place at the Oxford Radcliffe Hospitals NHS Trust.

29 Mar 2011

Efficacy News and Research

EPA approves Clorox DISPATCH disinfectant towels registration to fight against C. difficile

Abbott launches MitraClip system to treat MR in Australia

MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF

BioSante completes patient enrollment in LibiGel Phase III trial against HSDD

Pharmasset commences PSI-7977 Phase 2b study against HCV

Pathfinder cell-based therapy reverses diabetes in mouse model

Vexim granted FDA approval for COHESION bone cement

Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV

Navy sonar experts develop new medical device for stroke detection

Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

USPTO issues patent to Somaxon's Silenor food effect

Positive results from Vertex VX-770 Phase 3 trial against CF

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

PHT announces availability of NetPRO eClinical solution for public

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

International Phase II trial to study LY2181308 efficacy in patients with lung cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News